PET scans, which can detect changes in the brain due to Alzheimer's disease, can improve the diagnosis and medical care of people with dementia and similar symptoms.
An innovative type of brain scan can improve the care of people with Alzheimer's disease, dementia, and other forms of cognitive impairment.
The researchers came to this conclusion after analyzing the initial results of a study examining the clinical effect of a new type of screening called amyloid PET imaging.
The study is a national experiment involving more than 11,000. People with mild cognitive impairment (MCI) or dementia symptoms registered in 595 regions across the United States.
This is the first study of its kind, and all participants are Medicare, US federal health beneficiaries. Insurance plan.
The results of a first phase of research in a JAMA article now suggest that providing amyloid PET screening results to physicians may affect the medical management of people with dementia symptoms.
In about two-thirds of the cases, the doctors changed their thoughts about drugs, counseling, and other medical decisions after seeing amyloid PET imaging results.
In addition, in more than one third of the cases, doctors diagnosed the causes and symptoms.
Gil We were impressed, ik says the leading author Gil D.
Symptoms may worsen over time until a person can no longer take care of himself and live independently.
According to Alzheimer's Disease International's 2018 report, there are around 50 million people worldwide with dementia and this figure is set to three in 2050.
Alzheimer's blood test detected brain damage before symptoms The testing of blood for a protein leaking from the brain cells that have been tested can make it possible to detect Alzheimer's disease long before symptoms occur. Two-thirds of dementia patients have Alzheimer's disease. The rest is vascular, mixed, Lewy body or frontotemporal dementia. All of these conditions affect the brain and involve the loss of brain cells.
In the US, where Alzheimer's is the sixth cause of death, the Alzheimer's Association estimates that there are about 5.8 million people.
MCI is a condition in which a person may experience symptoms similar to early dementia.
The underlying cause may not be a progressive disease that kills brain cells. For example, the drug may be a result of side effects, depression or vitamin B-12 deficiency.
Brain plaques and amyloid PET imaging
One of the distinguishing features of Alzheimer's disease is the accumulation of toxic plaques of the amyloid protein. In the brain. Until recently, the only way to detect this vessel was to conduct postmortem tests on the brain tissue.
Now, thanks to the imaging of amyloid PET, doctors are able to detect brain plaques in people with Alzheimer's live.
With such medical imaging, the individual receives a chemical tracer injection before entering the scan. The tracer goes to the brain and adheres to any amyloid plate that may be present. These appear later in the scan.
Although there is no treatment for Alzheimer's disease, the ability to better diagnose in the early stages can help doctors write the right treatment and give patients and their families time to prepare for the future. It can also improve the selection of appropriate candidates for drug trials of Alzheimer's.
If the amyloid PET scan can rule out Alzheimer's disease as a person's cause of dementia symptoms, physicians may be able to evaluate other causes. Some may even be reversible, such as medication, sleep disorder or mood disorders.
The Food and Drug Administration (FDA) has approved the use of chemical tracers performing an amyloid PET scan, requires for diagnosis of dementia.
Maria C. Carrillo is a science officer who is the head of the Alzheimer's Association, one of the sponsors of the study. “The amyloid PET imaging has provided very reliable, wide-ranging evidence that it can be a powerful tool in improving the accuracy of Alzheimer's diagnosis and, in particular, leading to better medical management in difficult-to-diagnose cases, Çalış he said. >
”It's important, bir he adds, adding: PET Those who need to view amyloid PET are more accessible.“
The first phase of IDEAS study
Study Evidence for Imaging Dementia – Amyloid Screening (IDEAS) is the first phase of the study.
The researchers examined data to analyze how 11.409 amyloid PET imaging changed physicians' diagnosis and medical treatment preferences. The primary measure was to make changes to prescription medicines and decisions that would advise patients and their families on safety and planning.
The secondary measure assessed by the team caused amyloid PET scans to change the diagnosis of doctors. The team also explored how screening influences the direction of Alzheimer's drug trials.
The results showed that more than 60 percent of the participants had amyloid PET scans that led doctors to change their minds on medical issues.
The correct diagnosis of those involved in a drug trial specific to this situation increases the reliability of the trial results.
Professor Rabinovici also stated that ece Alzheimer's drugs can worsen cognitive decline in people with other brain diseases Rab. Because of the results published in 2020, it will examine the effect of amyloid PET imaging on health outcomes. To do this, the amyloid PET scan will include a comparison with people with similar symptoms that do not undergo screening.
The post Dementia: Amyloid PET scans can improve diagnosis and care appeared first on Binbon.
Get real time update about this post categories directly on your device, subscribe now.